Join ProQR Therapeutics for a virtual investor and analyst educational event featuring Gideon Hirschfield, MA (Oxon), MB BChir (Cantab), FRCP, PhD (Toronto Centre for Liver Disease), who will join company management to discuss the unmet need and current treatment landscape in cholestatic liver disease, with a focus on biliary atresia.

The event will provide an in-depth review of the role of bile acids and NTCP modulation in cholestatic liver disease, with a focus on biliary atresia. ProQR will review the recently reported AX-0810 Phase 1 target engagement data and discuss the translational rationale and clinical development strategy for NTCP modulation in biliary atresia, including the framework for evaluating upcoming next-generation AX-0811 Phase 1 data and its potential to treat cholestatic disease.

A live question and answer session with covering analysts will follow the formal presentations.